|Day Low/High||300.85 / 308.37|
|52 Wk Low/High||187.72 / 309.66|
Overall the charts and indicators of UNH are constructive.
In this era of economic turbulence created by a public health crisis, this large health insurance company actually affirmed full year guidance for both earnings and net income.
Are the markets ready for a pause in this dramatic rebound? We are several weeks behind Europe in battling this pandemic and U.S. numbers are far worse. Time will tell.
These names should do well as long as the coronavirus is a threat, and still continue to grow once it is past.
UNH has moved up strongly from its March nadir so traders and investors should approach from the long side.
You can sell any stock that's up and take that money to the bank and no one will say, "sorry that was made off of euphoria, we can't take it."
I have been among the most wary of China and its ability to change. I remain that way. But the U.S. got more than I ever thought.
One concern for traders and investors would be that the good cheer created by the development of this Phase One deal, as well as actions taken by the FOMC, are nearing or at the point where the headline risk points in the other direction.
Earnings reports are solid but this overbought market is looking for a good reason to consolidate a big move.
The big tech names are once again surging, and as long as they keep their noses clean, that should continue.
This company made headlines in 2019, and I'm betting on it as a great play -- in many senses of the word -- for this new year.
Despite fluff and puff of UNH's analysts' day, little here screams for getting in right now.
There is no doubt in my mind that the firm is executing at a high level.
Time to review the charts and indicators.
UnitedHealth Group and JPMorgan are both bucking other trends to rise as more moderate leanings start to dominate the Democratic horse race.
Prices have rocketed higher since early October.
These are the 10 reasons why we keep going up, despite all the bad news.
The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.
After seeing the idea raised -- and derided -- I found that the Dow has been over 27,000 twice this year and each time it did this....
I have the answer behind the conundrum that forces stocks up that should be going lower.
These stocks's earnings were 'not as bad as feared,' and here are some more names that pushed the NABAF narrative.
There are plenty of senior growth companies that can still move higher.
The Fed is doing this right. Let me repeat... the Fed is not screwing this up.
As mentioned earlier, breadth was only 2-1 positive with UnitedHealth , JPMorgan and Johnson & Johnson responsible for a large portion of the market's gains. Bond yields rose, aiding the rate-sensitive banks (who generally met expectations). FANG ha...
"Only" about 2-1 advancers over decliners as UnitedHealth Care , JP Morgan and Johnson & Johnson account for a disproportionate amount of the market's rally.
Citigroup and Lululemon are on the radar this morning.